Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate if co-treatment of acromegalic patients, who
beforehand are considered well-controlled on SA monotherapy, with pegvisomant and SA will
improve insulin sensitivity and glucose tolerance, and if these effects of co-treatment can
be obtained at a neutral cost as compared to SA mono therapy.
Second to investigate body composition, substrate metabolism, symptoms, intrahepatic and
intramyocellular fat.
Phase:
N/A
Details
Lead Sponsor:
University of Aarhus
Collaborators:
Aarhus University Hospital Aarhus University Hospital Skejby Forskningsrådet for Sundhed og Sygdom The Research Council for Health and Disease, Denmark